Antengene Corporation Limited (HKG:6996)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.460
+0.460 (11.50%)
Mar 10, 2026, 4:08 PM HKT
43.41%
Market Cap 2.72B
Revenue (ttm) 92.43M
Net Income (ttm) -250.49M
Shares Out 679.24M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,444,756
Average Volume 3,982,954
Open 4.120
Previous Close 4.000
Day's Range 4.020 - 4.480
52-Week Range 2.100 - 8.160
Beta 0.84
RSI 62.92
Earnings Date Mar 24, 2026

About Antengene Corporation

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 152
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6996
Full Company Profile

Financial Performance

In 2024, Antengene Corporation's revenue was 91.95 million, an increase of 36.62% compared to the previous year's 67.31 million. Losses were -319.25 million, -45.07% less than in 2023.

Financial numbers in CNY Financial Statements

News

Antengene Secures Malaysian Approval For XPOVIO In Relapsed/Refractory DLBCL

(RTTNews) - Antengene Corporation Limited (6996.HK) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application (sNDA) for XPOVIO (selinexor...

2 months ago - Nasdaq

Antengene: NMPA Approves IND Application For Phase Ib/II CLINCH-2 Study With ATG-022

(RTTNews) - Antengene Corporation Limited (6996.HK) announced that China National Medical Products Administration or NMPA has approved the investigational new drug application for the Phase Ib/II CLIN...

3 months ago - Nasdaq